MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+37.1%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$622M
AUM Growth
+$622M
(+46%)
Cap. Flow
+$83.7M
Cap. Flow
% of AUM
13.46%
Top 10 Holdings %
Top 10 Hldgs %
55.49%
Holding
44
New
12
Increased
14
Reduced
4
Closed
6
Top Buys
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
$23.9M |
| 2 |
Sutro Biopharma
STRO
|
$23.1M |
| 3 |
Natera
NTRA
|
$15.8M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$11.5M |
| 5 |
89bio
ETNB
|
$11.3M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$16.9M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$16.1M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$14.4M |
| 4 |
Viking Therapeutics
VKTX
|
$14.4M |
| 5 |
Structure Therapeutics
GPCR
|
$9.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $130M | 20.95% | 7,648,268 | – | – |
|
2
Geron
GERN
$893M
| $34.6M | 5.56% | 10,475,675 -239,945 | -2% | -$792K |
|
|
3
Iovance Biotherapeutics
IOVA
$807M
| $32.6M | 5.24% | 2,200,000 -1,089,470 | -33% | -$16.1M |
|
|
4
Zentalis Pharmaceuticals
ZNTL
$122M
| $23.9M | 3.84% | +1,516,183 | New | +$23.9M |
|
5
iTeos Therapeutics
ITOS
| $23.8M | 3.83% | 1,745,943 | – | – |
|
|
6
Sutro Biopharma
STRO
$72.7M
| $23.1M | 3.72% | +4,096,619 | New | +$23.1M |
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $22.5M | 3.62% | 480,588 +2,354 | +0.5% | +$110K |
|
8
Olema Pharmaceuticals
OLMA
$375M
| $22.1M | 3.56% | 1,953,690 +96,554 | +5% | +$1.09M |
|
9
Madrigal Pharmaceuticals
MDGL
$9.76B
| $16.4M | 2.64% | 61,399 +20,489 | +50% | +$5.47M |
|
|
10
Natera
NTRA
$23.1B
| $15.8M | 2.54% | +172,413 | New | +$15.8M |
|
11
Werewolf Therapeutics
HOWL
$59.9M
| $15.5M | 2.49% | 2,388,011 | – | – |
|
12
MoonLake Immunotherapeutics
MLTX
$3.54B
| $14.9M | 2.39% | 296,050 +1,474 | +0.5% | +$74K |
|
|
AVDL
13
Avadel Pharmaceuticals
AVDL
$1.43B
| $14.7M | 2.37% | 871,149 +206,163 | +31% | +$3.48M |
|
14
Insmed
INSM
$28.8B
| $14.4M | 2.32% | 530,794 +2,644 | +0.5% | +$71.7K |
|
15
ALX Oncology
ALXO
$62.7M
| $14.1M | 2.27% | 1,268,471 +3,712 | +0.3% | +$41.4K |
|
|
16
Viking Therapeutics
VKTX
$3.04B
| $12.3M | 1.98% | 150,000 -175,284 | -54% | -$14.4M |
|
17
Intellia Therapeutics
NTLA
$1.22B
| $11.9M | 1.91% | 432,598 +50,000 | +13% | +$1.38M |
|
18
Regenxbio
RGNX
$451M
| $11.6M | 1.86% | 549,078 | – | – |
|
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $11.5M | 1.84% | +245,590 | New | +$11.5M |
|
|
MORF
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $11.5M | 1.84% | 325,333 +1,591 | +0.5% | +$56K |
|
|
21
89bio
ETNB
$1.34B
| $11.3M | 1.81% | +967,742 | New | +$11.3M |
|
22
Viridian Therapeutics
VRDN
$1.5B
| $10.8M | 1.73% | 614,010 +514,010 | +514% | +$9M |
|
23
Fulcrum Therapeutics
FULC
$351M
| $10.7M | 1.73% | +1,137,108 | New | +$10.7M |
|
24
Xeris Biopharma Holdings
XERS
$1.26B
| $9.21M | 1.48% | 4,166,496 +319,264 | +8% | +$706K |
|
25
Axsome Therapeutics
AXSM
$6.05B
| $9.11M | 1.46% | 114,127 +20,740 | +22% | +$1.66M |
|